

BioTime Co-CEO Dr. Michael West to Deliver Keynote Presentation at GTC Bio Stem Cell Summit on April 6

April 4, 2017

Will Present on the Promise of Pluripotent Cells in Advanced Therapeutics and the Company's Plans to Develop Applications in Human Aging

ALAMEDA, Calif.--(BUSINESS WIRE)--Apr. 4, 2017-- BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced that Co-Chief Executive Officer Michael D. West, Ph.D., is delivering a keynote presentation at the [GTC Bio Stem Cell Summit](#), on April 6 at the [Hyatt Regency](#) in Boston, Massachusetts.

Titled "The Promise of Pluripotency in the Manufacture of Advanced Cell-Based Therapeutics," Dr. West's keynote presentation is scheduled for Thursday, April 6 at 10:40 a.m. EDT. It will provide an industry update on therapeutic uses of human pluripotent cell-based regenerative medicine, including BioTime's clinical-stage OpRegen[®] and Renevia[®] programs. Dr. West will also discuss the company's preclinical products in development for Type II diabetes and heart disease, as well as the emerging field of induced tissue regeneration (iTRTM) and their potential impact on the future of human aging.

More information about the Stem Cell Summit is available at www.gtcbio.com/conferences/stem-cell-summit/.

More information on iTR is available via this video: <https://www.youtube.com/watch?v=Owx2-jzqJHQ>.

About BioTime

BioTime is a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases. Our clinical programs are based on two platform technologies: pluripotent stem cells and cell/drug delivery platform technologies. The foundation of our core therapeutic technology platform is pluripotent cells that are capable of becoming any of the cell types in the human body. The foundation of our cell delivery platform is its HyStem[®] cell and drug delivery matrix technology. The Company's current clinical programs are targeting three primary sectors, aesthetics, ophthalmology and cell/drug delivery. We also have significant equity holdings in two publicly traded companies, Asterias Biotherapeutics, Inc. ("Asterias") and OncoCyte Corporation ("OncoCyte"), which we founded and which, until recently, were our majority-owned consolidated subsidiaries.

BioTime common stock is traded on the NYSE MKT and TASE under the symbol BTX. For more information, please visit www.biotimeinc.com or connect with the company on [Twitter](#), [LinkedIn](#), [Facebook](#), [YouTube](#), and [Google+](#).

To receive ongoing BioTime corporate communications, please click on the following link to join our email alert list: <http://news.biotimeinc.com>.

View source version on businesswire.com: <http://www.businesswire.com/news/home/20170404005517/en/>

Source: BioTime, Inc.

Investor Contact:

EVC Group, Inc.

Brian Moore, 310-770-0389

bmoore@evcgroup.com

or

Media Contact:

[Gotham Communications](#), LLC

Bill Douglass, 646-504-0890

bill@gothamcomm.com